Creo Medical Group (LON:CREO) Posts Quarterly Earnings Results

Creo Medical Group (LON:CREO) issued its earnings results on Friday. The company reported GBX (0.04) EPS for the quarter, Digital Look Earnings reports. Creo Medical Group had a return on equity of 32.72% and a net margin of 768.18%.The firm had revenue of GBX 600 million during the quarter.

Creo Medical Group Stock Up 28.4%

Shares of LON:CREO traded up GBX 3.23 on Friday, hitting GBX 14.60. 4,625,965 shares of the company traded hands, compared to its average volume of 824,924. The stock has a 50 day simple moving average of GBX 12.08 and a 200-day simple moving average of GBX 12.16. The company has a quick ratio of 2.19, a current ratio of 5.28 and a debt-to-equity ratio of 6.90. The company has a market cap of £60.22 million, a PE ratio of -14.60 and a beta of 1.62. Creo Medical Group has a 52 week low of GBX 9.52 and a 52 week high of GBX 18.50.

Analysts Set New Price Targets

Separately, Shore Capital Group reissued a “house stock” rating on shares of Creo Medical Group in a report on Thursday, April 16th.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.